# Phase III Placebo-controlled Study of V260 (RotaTeq™) in Japanese Healthy Infants (V260-029)(COMPLETED)

> **NCT00718237** · PHASE3 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 762 (actual)

## Conditions studied

- Rotavirus
- Gastroenteritis

## Interventions

- **BIOLOGICAL:** Rotavirus Vaccine, Live, Oral, Pentavalent (V260, RotaTeq™)
- **BIOLOGICAL:** Comparator: Comparator: Placebo (unspecified)

## Key facts

- **NCT ID:** NCT00718237
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-08
- **Primary completion:** 2009-08
- **Final completion:** 2009-08
- **Target enrollment:** 762 (ACTUAL)
- **Last updated:** 2017-04-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00718237

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00718237, "Phase III Placebo-controlled Study of V260 (RotaTeq™) in Japanese Healthy Infants (V260-029)(COMPLETED)". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT00718237. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*